文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

风湿病学领域未满足的需求:2022年靶向治疗进展会议报告

Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022.
PubMed 文献 · Ann Rheum Dis · 2023-01-26

第22届国际靶向治疗进展会议汇集100余位风湿病学、免疫学等领域专家,分五组讨论类风湿关节炎、银屑病关节炎、中轴型脊柱关节炎、系统性红斑狼疮和结缔组织病的未满足需求。会议强调临床试验设计创新,识别出难治性疾病治疗、疾病内型、前疾病状态及分子标志物等优先需求。

要点

  • 难治性疾病患者的治疗和试验开发仍是类风湿关节炎最重要的未满足需求之一。
  • 狼疮和脊柱关节炎领域强调需考虑疾病内型。
  • 结缔组织病领域关注早期和未分化疾病的分子、细胞和临床信号以识别新药靶点。

核心结论

  • 风湿病学领域仍强烈需要为治疗难治性疾病患者开发疗法和治疗策略。
  • 日益明确需要更好地理解这些疾病的自然史包括其「前疾病」状态,并识别包括组织水平的分子特征以促进诊断和治疗。

研究设计与样本

  • 第22届年度国际靶向治疗进展会议在SARS-CoV-2大流行导致2年中断后召开,汇集100余位基础科学家和临床研究人员。
  • 会议设置五个风湿病疾病特异性分组:类风湿关节炎、银屑病关节炎、中轴型脊柱关节炎、系统性红斑狼疮和结缔组织病。
  • 各组专家被要求识别和优先排序当前临床与转化研究的未满足需求,并强调临床试验设计创新。

主要发现

  • 类风湿关节炎组识别出难治性疾病患者的疗法和试验开发仍是最重要的未满足需求之一。
  • 狼疮和脊柱关节炎领域强调需考虑疾病内型。
  • 类风湿关节炎组还识别出需更好理解类风湿关节炎自然史、前类风湿关节炎状态并最终实现精准医学。
  • 结缔组织病领域专家关注需更好识别早期和未分化疾病的分子、细胞和临床信号以识别新药靶点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些未满足需求是基于领域内专家临床医生和科学家的共识识别的,本文档可服务于个人研究者、机构和产业界以帮助优先排序其科学活动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To detail the unmet clinical and scientific needs in the field of rheumatology. After a 2-year hiatus due to the SARS-CoV-2 pandemic, the 22nd annual international Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. Breakout sessions were convened with experts in five rheumatological disease-specific groups including: rheumatoid arthritis (RA), psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus and connective tissue diseases (CTDs). In each group, experts were asked to identify and prioritise current unmet needs in clinical and translational research, as well as highlight recent progress in meeting formerly identified unmet needs. Clinical trial design innovation was emphasised across all disease states. Within RA, developing therapies and trials for refractory disease patients remained among the most important identified unmet needs and within lupus and spondyloarthritis the need to account for disease endotypes was highlighted. The RA group also identified the need to better understand the natural history of RA, pre-RA states and the need ultimately for precision medicine. In CTD generally, experts focused on the need to better identify molecular, cellular and clinical signals of early and undifferentiated disease in order to identify novel drug targets. There remains a strong need to develop therapies and therapeutic strategies for those with treatment-refractory disease. Increasingly it is clear that we need to better understand the natural history of these diseases, including their 'predisease' states, and identify molecular signatures, including at a tissue level, which can facilitate disease diagnosis and treatment. As these unmet needs in the field of rheumatic diseases have been identified based on consensus of expert clinicians and scientists in the field, this document may serve individual researchers, institutions and industry to help prioritise their scientific activities.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Winthrop KL, Isaacs JD, Mease PJ, et al. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Ann Rheum Dis. 2023. PMID: 36702529. doi:10.1136/ard-2022-223528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。